Publications by authors named "E Seward"
Article Synopsis
- HPK1 is a negative regulator of T-cell receptor signaling, and its inhibition can enhance immune responses and work well with immune checkpoint inhibitors in cancer models.
- Researchers have discovered a new series of isoquinoline compounds that effectively inhibit HPK1 and promote T-cell activity through fragment-based screening.
- The best candidate from these efforts showed strong inhibition of HPK1, excellent selectivity for other kinases, a good safety profile, and favorable pharmacokinetic properties for potential cancer immunotherapy use.
Botulinum neurotoxin type A (BoNT/A) is a biopharmaceutic widely used for the treatment of neurological diseases and in aesthetic medicine to achieve months-long paralysis of target muscles and glands. Large numbers of mice are used in the mouse bioassay (MBA) for various botulinum-related applications including batch release potency testing, antitoxin testing, countermeasure development, and basic research. BoNT/A intoxication causes severe suffering to the mice used for testing, and application-specific, non-animal alternatives are urgently needed.
View Article and Find Full Text PDFBackground: Ustekinumab was approved in 2016 for the treatment of moderate-severe Crohn's disease (CD). Clinical trials and real-world studies have suggested ustekinumab to be a safe and effective treatment; however, studies to date infrequently use imaging techniques to predict response to biologics in CD.
Objectives: We assessed the 2-year real-world effectiveness and safety of ustekinumab in a tertiary CD cohort with the use of novel imaging techniques.
Background: Measurement of faecal haemoglobin using faecal immunochemistry testing is recommended in patients presenting with symptoms suspicious for colorectal cancer, to aid in triage and prioritization of definitive investigations. While its role in colorectal cancer has been extensively investigated, the ability of faecal immunochemistry testing to detect adenomas in symptomatic patients is unclear.
Methods: A multicentre prospective observational study was conducted between April 2017 and March 2019, recruiting adults from 24 hospitals across England and 59 general practices in London who had been urgently referred with suspected colorectal cancer symptoms.